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Patients’ preferences within randomised trials:
systematic review and patient level meta-analysis
Preference Collaborative Review Group
ABSTRACT
Objective To systematically review fully randomised
patient preference trials and to explore the impact of
preferences on attrition and outcome by meta-analysis of
patient level data.
DatasourcesCitationsearchusingScienceCitationIndex
and Google Scholar and search of the main electronic
databases (Medline, CINAHL, Embase, and AMED) with a
combination of key words.
StudyselectionFullyrandomisedpatientpreferencetrials
that compared treatments for any clinical condition were
included. Other types of preference trials and crossover
trialswereexcluded.Otherinclusioncriteria:participants
aged 16 years and over; primary, self-reported outcomes
measured on a continuous numerical scale. From 167
studies identified and screened, 17 were identified as
fully randomised patient preference trials.
Data synthesis Of the 17 trials identified, 11 authors
provided raw data for the meta-analysis. Data collected
were baseline and follow-up data for the main outcome,
randomised allocation data, preference data, and
demographic data. Baseline and first post-intervention
follow-up data for the main outcome were standardised.
To improve homogeneity, data for only the eight
musculoskeletal trials (n=1594) were combined. To
estimate the effects of preferences on outcomes and
attrition,threegroupswerecompared:patientswhohada
preferenceandwererandomlyallocatedtotheirpreferred
treatment; patients who had a preference and were
randomly allocated to the treatment they did not prefer;
and patients who had no preference.
Results Patients who were randomised to their preferred
treatmenthadastandardisedeffectsizegreaterthanthat
ofthosewhowereindifferenttothetreatmentassignment
(effect size 0.162, 95% confidence interval 0.011 to
0.314; P=0.04). Participants who received their preferred
treatment also did better than participants who did not
receive their preferred treatment (effect size 0.152,
−0.035 to 0.339), although this was not statistically
significant (P=0.11). Participants allocated to their
undesired treatment had outcomes that were no different
from those who were indifferent. Participants who were
allocated to their undesired treatment were less likely to
be lost to first follow-up compared with indifferent
participants(oddsratio1.70,1.076to2.693;P=0.02).No
difference was found in attrition between patients
allocated to their preference and those who were
indifferent.
Conclusions Preferences among patients in
musculoskeletal trials are associated with treatment
effects. In open randomised trials, preferences should be
ascertained before randomisation.
INTRODUCTION
Therandomisedcontrolledtrialisacknowledgedasthe
mostscientificallyrigorousstudydesignforevaluating
medicalinterventions.
1Althoughrandomallocationis
intended to evenly distribute characteristics of partici-
pants that may affect outcome and remove selection
bias,itmaynotdealwithotherpotentialbiases.Oneof
these is patients’ preferences. Random allocation will
distribute patients with a preference for a given
intervention between the intervention groups in
similar proportions, as it does with physical character-
istics such as weight or height. What it cannot do,
however, is deal with the post-randomisation effects of
these preferences on treatment outcomes. Because
patients’ preferences are not dealt with in the
randomisation process, they are viewed as a potential
threat to the validity of trials.
2 The effect of patients’
preferences on treatment outcomes in randomised
controlled trials is, however, uncertain.
3
Patients with strong preferences may decline to
participate; in a trial in which strong preferences exist
and a large number of patients refuse randomisation,
the external validity will be adversely affected. When
this occurs, generalisability of the results to a wider
populationwillbelimited.
4Ifpatientswithpreferences
consent to randomisation, this may also affect its
internal validity.
Inarandomisedcontrolledtrial,patientsmayhavea
preference either for the standard treatment or for the
newtreatmentbeingevaluatedormaybeindifferentto
bothtreatments.Ifpatientswithpreferencesconsentto
be randomised then some patients will get their
preferred treatment and others will not. Those who
receive their preferred treatment might be better
motivated and comply better with the treatment
programmes and report better outcomes.
5 Patients
who do not receive their preferred treatment may
experience “resentful demoralisation,”
6 may be less
motivated, may not comply with the treatment
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up, and may even drop out of the trial and thereby
introduce bias that affects the internal validity of the
trial.
5 Effects of preference are likely to be more
apparentinunblindedtrialsinwhichpatientsareaware
of the treatment they are receiving and the outcome
measure is subjective and self reported by the patient.
As well as the direct effects of patients’ preferences
oncomplianceandmotivation,a“therapeuticeffect”of
patients’ preferences can occur.
7 These are the
psychological effects that influence outcomes and are
similartotheplaceboeffect.
7Thetherapeuticeffectsof
patients’preferencesareproblematicfortrialsbecause
these seek to determine or assess the physiological or
pharmacological effects of an intervention. Disentan-
gling the psychological effects of patients’ preferences
from the physiological effects is complex.
8
One approach to dealing with patients’ preferences
is the partially randomised preference design also
known as a patient preference trial or comprehensive
cohortdesign.
25Patientswithoutstrongpreferencesfor
a treatment are randomised, and those with strong
preferences are given their choice, resulting in a four
armed trial.
2 Such a design enables comparisons
between patients with and without a preference and
an exploration of patients’ characteristics associated
with preference. An important disadvantage of this
design is that the outcome may be affected by
uncontrolled confounders in the non-randomised
groups,
9 which may bias the results.
10 Whether the
randomised group should be compared with the non-
randomised group is therefore debatable.
96
An alternative approach is a standard randomised
controlled trial in which, after participants have given
consent in the usual way and before randomisation,
patients’ preferences are recorded: this design would
be a fully randomised preference trial.
6 These prefer-
ences are then taken into account in the analysis of the
trial. Such an approach has been used in some trials,
w1
and at least one apparently observed a preference-
treatmentinteraction.
w2Thisinteraction,however,was
not statistically significant. A potential criticism of this
approach is that ignoring patients’ preferences and
proceedingwithrandomisationisunethical.However,
acounterargumentisthatignoringpreferencesmaybe
ethicalifallthetreatmentsbeingofferedarebelievedto
beeffectiveandpatientsgivefullyinformedconsent.
w3
Detecting patients’ preference-treatment inter-
a c t i o n sw i t h i nt r i a l si sd i f f i c u l t ,a st r i a l sa r en o t
sufficiently powered to detect them.
104 However,
Torgerson and Sibbald suggested standardising the
wayinwhichinformationonpreferencesisobtainedin
trialssothatthetrialscouldbeusedinmeta-analysisto
assess the effect of preferences on outcomes.
11
King and colleagues recently systematically
reviewed the effects of participants’ preferences in
randomised controlled trials.
512They investigated the
effects of preferences on outcomes and recruitment to
trials and the influence of preferences on attrition.
Their review identified 34 randomised controlled
trials, but only two of these were fully randomised
patient preference trials.
13w1 The review, which used
evidence from partially randomised preference trials,
found no evidence that preferences influenced attri-
tion.Itfoundsomeevidenceofaneffectonoutcomesin
someofthepreferencetrialsandnoeffectonoutcomes
in the two conventional randomised controlled trials.
Thetrialsandstudiesincludedin the reviewwere very
heterogeneous,andtheauthorsreportedthattheywere
therefore unable to “reach definitive conclusions for
any particular clinical field.”
5
Herewereporttheresultsofasystematicreviewand
an individual patient data analysis of fully randomised
patient preference trials. The aim of the review was to
assess whether preferences had an interaction with
effectiveness of treatment and whether attrition from
the study was different between patients who received
theirpreferredtreatment,thosewhodidnot,andthose
who had no preference. This review differs from the
previousreviewbyKingandcolleaguesinthatwewere
interested only in fully randomisedpreference designs
and we also sought patient level data for our analysis.
METHODS
We wanted to identify all trials that have used the fully
randomised preference trial design. The extensive
systematic review by King and colleagues (2005)
searched for papers published between 1966 and
September 2004 and identified only two that were
fully randomised patient preference trials.
5 To find
additional papers we did a citation search using
Torgerson et al (1996) and Torgerson and Sibbald
(1998),
611 which were the first papers to describe the
fully randomised patient preference trial. We used
Science Citation Index and Google Scholar to do the
citation search. In Science Citation Index, we selected
the two papers on which the citation search was to be
based.Thedatabasethenidentifiedallarticlesthathad
cited the papers. When we used Advanced Scholar
Excluded (not fully randomised patient
preference trials, or irrelevant) (n=142)
Fully randomised patient preference trials excluded from
  meta-analysis (n=9):
    Main trial not analysed (n=1)
    Needed ethical permission before release of data (n=1)
    Data unavailable (n=4);
    To improve clinical homogeneity (n=3)
Potentially relevant randomised controlled trials
identified and screened for retrieval (n=167)
Randomised controlled trials retrieved
for more detailed evaluation (n=25)
Excluded (not fully randomised
patient preference trials) (n=8)
Potentially appropriate trials to be
included in meta-analysis (n=17)
Fully randomised patient preference trials
with usable information on outcome (n=8)
Flow chart of studies included in meta-analysis
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“Biology, life sciences, and environmental science”
and “Medicine, pharmacology, and veterinary
science,” and the date range 2000 to October 2006.
We did our first search on the terms “random, trial,
preference, Torgerson, Sibbald” and a second search
on the terms “random, trial, preference, Torgerson,
Klaber”.WealsomadesearchesinMedline,CINAHL,
Embase1996to2006,andAMEDonthesearchterms
“patient preference$ trial$”. We identified relevant
studies initially by title and abstract and finally by full
text.Inaddition,weincludedtrialsthatwereknownto
us through personal knowledge.
We included only fully randomised preference
trials.
6 Other inclusion criteria were participants
16 years and over and primary self reported outcomes
measured on a continuous scale. We included only
trials with self reported outcomes, as trials with
outcomes reported by clinicians (or another assessor)
are unlikely to be influenced by patients’ preferences.
Additionally, we chose to focus on only one self
reported primary outcome and exclude secondary
outcome measures to avoid type I error. If trialists had
used more than one primary outcome measure, we
used the measure that was most common to all the
studies, as this would tend to ameliorate the statistical
heterogeneity between the studies. We selected out-
comes measured on a numerical scale, as these would
be more powerful than dichotomous outcomes. We
excluded trials in which patients were given their
choice of treatment and crossover trials. We checked
the generation of the randomisation sequence, con-
cealment of randomisation allocation, and systematic
differences in attrition of participants between the
comparison groups to ensure the methodological
quality of the included studies.
Weinitiallyapproachedtheauthorsoftheidentified
trials by email to ask if they would be willing to release
theirdataforthestudy.Iftheyexpressedaninterest,we
sent them the protocol for this study with a request for
Table 1 |Description of identified trials
Adamson et al,
2005
w3
Therapy preference and treatment outcome in clients with mild to
moderate alcohol dependence
Science Citation Index and known to York
Trials Unit
Yes
Carr et al, 2005
w4 Arandomizedtrialcomparingagroupexerciseprogrammeforback
pain patients with individual physiotherapy in a severely deprived
area
DT was joint investigator Yes
Hardy et al*,
1995
13; Shapiro et
al, 1994
16
Effects of treatment duration and severity of depression on the
effectiveness of cognitive-behavioural and psychodynamic
interpersonal psychotherapy
Cited in systematic review by King et al, 2005 No
Hay et al, 2003
w5;
Thomas et al,
2004
w6
What influences participants’ treatment preference and can it
influenceoutcome?Resultsfromaprimarycare-basedrandomised
trial for shoulder pain
Science Citation Index Yes
Johnson et al,
2007
w7
Active exercise, education and cognitive behavioural therapy for
persistent disabling low back pain: a randomised controlled trial
DTwasco-authorontrial(publicationpending
at the time of review)
Yes
Kendrick et al,
2005
17
A trial of problem-solving by community mental health nurses for
anxiety, depression and life difficulties among general practice
patients: the CPN-GP study.
Science Citation Index No
Kitchener et al,
2006
w8
Laparoscopic versus open colpo-suspension—results of a
prospective randomised controlled trial
DT was joint investigator Yes
Klaber Moffett et al,
1999
w1
Randomised controlled trial of exercise for low back pain: clinical
outcomes, costs, and preferences
Cited insystematicreviewbyKingetal, 2005.
Science Citation Index, and DT was co-
investigator
Yes
Klaber Moffett et al,
2005
w2
Randomised trial of a brief physiotherapy intervention compared
with usual physiotherapy for neck pain patients: outcomes and
patients’ preference
Science Citation Index, and DT was co-
investigator
Yes
Klaber Moffett et al,
2006
w9
Randomized trial of two physiotherapy interventions for primary
careneckandbackpainpatients:“McKenzie”vsbriefphysiotherapy
pain management
Science Citation Index, and DT was co-
investigator
Yes
McLean et al,
publication
pending
w10
Arandomisedcontrolledtrialcomparinggradedexercisetreatment
and usual physiotherapy for patients with neck pain
Found from contacting JKM (publication
pending at the time of review)
Yes
Pepper et al, in
press
18
Female urinary incontinence: women’s preference for group or
individual treatment
DT saw conference poster (publication
pending at the time of review)
No
Salisbury et al,
2005
w11
Evaluation of a general practitioner with special interest service for
dermatology: randomised controlled trial.
DT noted when reading journal Yes
Salter et al,
2006
w12
Acupuncture for chronic neck pain: a pilot for a randomised
controlled trial.
DT advised on trial design (publication
pending at the time of review)
Yes
Sherman et al,
2005
19
Comparingyoga,exercise,andaself-carebookforchroniclowback
pain. a randomized controlled trial
DT noted when reading journal No
Simpson et al,
2000
20
Arandomisedcontrolledtrialtoevaluatetheeffectivenessandcost-
effectiveness of counselling patients with chronic depression
CitedinarticlebyvanSchaiketal,2004,which
was found on Medline
No
Unützer et al,
2002
21
Collaborative care management of late-life depression in the
primary care setting
CitedinarticlebyvanSchaiketal,2004,which
was found on Medline
No
*Reported strengths of preferences for interventions but not proportions.
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outcome measures, we calculated standardised base-
line and outcome scores for all patients by dividing
their scores by the baseline standard deviation for the
samplepopulationforthattrial.Inaddition,mosttrials
hadmultiplefollow-uppoints.Wethereforedecidedto
use the first follow-up point after treatment had
finished, as this would tend to minimise loss of data
andbemostlikelytoshowaneffectofpreferenceifone
existed.
Analysis
Toanalyseifpatients’preferencesinfluenceoutcomes,
we used multiple regression with dummy variables for
categorical predictors. We used SPSS version 14. The
dependentvariablewasthestandardisedfirstfollow-up
score, and the predicting variable was patient’s
preference for treatment. We adjusted the analysis for
baseline scores and categorical variables of trial and
treatment allocation, which adjusted for treatment
effects of individual interventions. In the regression
analyses,wetreatedstudyasafixedeffect.Wechecked
thisassumptionwithaheterogeneity testandfoundno
evidence of heterogeneity. For calculating the odds
ratiosforresponsetofirstfollow-upquestionnaires,we
used logistic regression analysis. The dependent
variable was missing data at first follow-up, and in the
analysis we adjusted for age, sex, trial, and severity of
condition at baseline. We compared the outcomes of
three preference groups: patients with a preference
whogotwhattheywanted,thosewithapreferencewho
did not get what they wanted, and those who had no
preference (that is, they were indifferent). We first
compared the two preference groups with the indiffer-
ent group; then we compared patients with a pre-
ference who were randomised to their desired
treatment with those who were randomised to their
undesired treatment and the indifferent group. We
assessed the methodological quality of the trials and
found them to be adequate, so we did not need to
include this in the analysis.
RESULTS
Our search identified 167 possibly relevant studies
(figure). After screening the abstracts and full papers,
the searches identified 17 trials that met the inclusion
criteria of this study (table 1), and we were able to
obtain the patient level data for 11 studies (table 2).
w1-
Table 2 |Summary of studies included in systematic review
Authors Population
Sample size
(No)
Mean age
(years) Intervention and comparison groups Primary outcome(s)
Follow-up points for
primary outcome
Adamson et al,
2005
w3
Patients with mild to
moderate alcohol
dependence
124 35.7 Twotypesofcounselling:foursessionsof
motivational enhancement therapy and
non-directive reflective learning, and no
further counselling
Drinking; global functioning (global
assessment scale)
6 months
Carr et al, 2005
w4 Patients with non-
specific low back pain
237 42.2 Group exercise programme (“back to
fitness”) v individual physiotherapy
Roland Morris disability
questionnaire
3 months*,
12 months
Hay et al, 2003
w5;
Thomas etal, 2004
w6
Shoulder pain 207 57.4 Steroid injection v physiotherapy Shoulder disability questionnaire 6 weeks*, 6 months
Johnsonetal,2007
w7 Low back pain 234 47.9 Educational pack containing booklet,
audio cassette with advice on self
management v aforementioned plus
group programme of exercise and
education using a cognitive behavioural
therapy approach
Roland Morris disability
questionnaire
3*, 9, and 15 months
Kitchener et al,
2006
w8
Women with proved
stress urinary
incontinence requiring
surgery
291 50.6 Laparoscopic v open colposuspension
surgery
Satisfaction with outcome (Bristol
female lower urinary tract symptom
questionnaire)
6w e e k sa n d6 ,1 2
and 24 months
Klaber-Moffett et al,
1999
w1
Low back pain 187 41.9 Progressive exercise programme v usual
care (under care of doctor and in some
cases referred for physiotherapy)
Roland Morris disability
questionnaire
6 weeks*, 6 months,
and 12 months
Klaber Moffett et al,
2005
w2
Patients with sub-acute
and chronic neck pain
268 48.0 Brief physiotherapy intervention v “usual”
physiotherapy
Northwick Park neck pain
questionnaire
3 months*,
12 months
Klaber Moffett et al,
2006
w9
Back and neck pain 315 45.0 Cognitivebehaviouralprinciples(solution
finding approach) v physical therapy
(McKenzie approach)
Roland Morris disability
questionnaire for back pain patients;
Northwick Park neck pain
questionnaire for neck pain patients.
6 weeks*, 6 months,
and 12 months
McLean et al,
publication
pending
w10
Neck pain 151 54.0 Graded exercise treatment v usual
physiotherapy
Northwick Park neck pain
questionnaire
6w e e k s ,6m o n t h s * ,
and 12 months
Salisbury et al,
2005
w11
Non-urgent skin
problems
556 46.2 Management by general practitioner with
special interest v usual hospital
outpatient care
Dermatology life quality index 6 weeks, 9 months
Salter et al, 2006
w12 Patients with chronic
neck pain
24 56.5 Acupuncture and usual general
practitioner care v usual general
practitioner care
Northwick Park neck pain
questionnaire
1 month, 3 months*
*Follow-up data used in meta-analysis (first follow-up data after intervention selected).
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whereby the participants indicated which treatment
they preferred or if they were indifferent to the
treatments.Ineightofthe11studies,thequestionnaires
hadbeencompleted“alone”(thatis,notinthepresence
of a healthcare professional or researcher) by the
participants. A researcher was present in the trial by
Johnson and colleagues (2007) but was advised not to
help the participants to complete the questionnaires.
w7
Theinformationtheparticipantshadavailabletothem
on the treatments was provided in information sheets.
In the trial by Hay and colleagues (2003) and Thomas
and colleagues (2004),
w5 w6 patients were asked to
complete the baseline questionnaires before the visit
of a research nurse who was blind to treatment
allocation, and patients did not complete follow-up
questionnaires in the presence of any treating health-
care professionals. In the trial by Adamson and
colleagues (2005),
w3 patients were asked what their
treatment preference was at the feedback session
immediatelybeforeallocationoftreatment;astandard
description was used for the two treatments, and the
trialists advised that they were scrupulous in establish-
ing a sense of equipoise in the minds of all personnel
involved in the trial.
The proportion of patients who had a preference in
the 11 trials ranged from 16% for a trial of a solution
finding approach to back pain to 85% for a trial
comparing general practitioner’s care with hospital
care for non-urgent skin problems (table 3).
w9 w11 The
median preference rate was 56% (interquartile range
43-63%).Thedatashow,therefore,thatforthissample
of fully randomised preference trials, most trial
participants were not indifferent to the treatment to
which they were going to be allocated.
Of the 11 studies with patient level data, eight
(n=1594) were interventions for musculoskeletal con-
ditions. Because the data we obtained were dominated
by musculoskeletal studies whose reported outcomes
were very much in accordance (that is, they reported
outcomesonpainanddisability),wedecidedtorestrict
our pooled analysis to these studies. Consequently,
clinicalheterogeneity wouldbereduced.Wefoundno
evidence of statistical heterogeneity between studies
(χ
2=6.02, df=8; P=0.64).
Within the musculoskeletal trials, we examined
whether patients with a preference were statistically
significantly different in terms of age, sex, and
standardised baseline scores from participants who
were indifferent. We found no differences in standar-
dised baseline scores (mean 0.261 for preference
group; 0.267 for indifferent group; 95% confidence
interval for mean difference −0.068 to 0.177; P=0.38)
but a difference in age (mean 48.57 for preference
group; 46.99 for indifferent groups; 0.21 to 2.96;
P=0.024). Women were more likely to have a
preference,althoughthiswasnotsignificantlydifferent
(46.3% (n=439) for women; 42.3% (n=271) for men;
−1% to 9%; P=0.12).
After adjustment for baseline score, trial, and
treatment allocation, in terms of treatment effect
overall, patients who received their preference had
significantlygreaterimprovementsthandidthosewho
were indifferent (mean effect size 0.162, 95%
Table 3 |Prevalence of preferences and characteristics of patients in trials. Values are numbers (percentages) unless stated otherwise
Authors Sample size Female
Mean (SD)
age (years) Indifferent
With
preference
With preference for
“experimental”
treatment
With preference for control:
usual care or alternative
treatment
Missing
preference data
Adamson et al,
2005
w3
122* 52 (42) 35.7 (35.7) 16 (13) 102 (84) 90 (88) 12 (12) 4 (3.3)
Carr et al, 2005
w4† 237 133 (56) 42.2 (10.9) 152 (64) 70 (30) 10 (14) 60 (86)‡ 15 (6)
Hay et al, 2003
w5;
Thomas et al,
2004
w6†
207 110 (53) 57.4 (13.4) 81 (39.1) 125 (60.4) 83 (66) 42 (34)‡ 1 (0.5)
Johnson et al,
2007
w7†
234 140 (60) 47.9 (11.2) 100 (42.7) 134 (57.3) 114 (85) 20 (15) 0 (0)
Kitchener et al,
2006
w8
291 291 (100) 50.3 (10.5) 141 (48.5) 144 (49.5) 134 (93) 10 (7) 6 (2.1)
Klaber Moffett et al,
1999
w1†
187 106 (57) 41.9 (8.9) 69 (36.9) 118 (63.1) 118 (100) (0) 0 (0)
Klaber Moffett et al,
2005
w2†
268 168 (63) 48.3 (14.6) 142 (53) 126 (47) 43 (34) 83 (66)‡ 0 (0)
Klaber Moffett et al,
2006
w9†
315 188 (60) 45.0 (15.1) 261 (82.9) 51 (16.2) 37 (73) 14 (27) 3 (1.0)
McLean et al,
publication
pending
w10†
151 90 (60) 54.0 (14.3) 66 (43.7) 82 (54.3)§ 34 (45) 41 (55)‡ 3 (2.0)
Salisbury et al,
2005
w11
556 327 (59) 48.0 (19.1) 63 (11.3) 474 (85.3) 328 (69) 146 (31) 19 (3.4)
Salteretal, 2006
w12† 24 18 (75) 47.7 (16.5) 9 (37.5) 15 (62.5) 15 (100) (0) 0 (0)
*Two missing people in dataset.
†Trials included in patient level data meta-analysis.
‡Physiotherapy was control treatment in these trials.
§Seven participants removed from dataset for meta-analysis as they had preference for treatment not available in trial.
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contrast, contrary to expectations, those patients with
a preference who did not receive their preferred
treatment had only a slight, non-significant difference
favouring an improvement relative to the indifferent
group (effect size 0.011, −0.142 to 0.164; P=0.89).
When we compared patients randomised to their
preferred treatment with those randomised to their
unpreferredtreatment,wefoundaneffectsizeof0.152
(−0.035to0.339),whichwasnotstatisticallysignificant
(P=0.11). The total number of participants included in
the analysis to compare the effects of preferences on
outcomes was 1398 (table 4).
Afteradjustmentforseverityofconditionatbaseline
(thatis,baselinescores),age,andsex,thosewhodidnot
receivetheirpreferenceweremorelikelytoreturntheir
questionnaire at first follow-up than were those who
were indifferent (odds ratio 1.70, 95% confidence
interval 1.08 to 2.69; P=0.02); those who did receive
their preference also had an increased response rate,
but this difference was not significantly different from
the indifferent group (odds ratio 1.26, 0.82 to 1.94;
P=0.29).Thecomparisonofthosewhodidnotgettheir
preference with those who did yielded an odds ratio of
1.35, but this was not significant (95% confidence
interval 0.78 to 2.33; P=0.29). The total number of
participants included in the analysis to compare the
effects of preferences on attrition was 1583 (table 5).
DISCUSSION
In this review, we identified 17 fully randomised
preference trials and obtained patient level data for 11
of these.These trials covered a range of conditionsbut
were mainly in musculoskeletal medicine where
patients are unblinded to their treatment and self
report quality of life outcomes. In these types of trials,
preferences are most likely to have an effect on
outcomes and attrition. In contrast with an earlier
review,
5 we have found some evidence to suggest that
preferences can modify treatment outcomes, although
these effects were not all in the expected direction. In
terms of increased study attrition, which is widely
hypothesisedtobeaffectedbypreference,wefoundthe
converse of what was expected: participants with a
preference who are randomised to the opposite
treatment are actually more likely to return follow-up
data than those who were indifferent.
Strengths and limitations
By pooling the data from the eight musculoskeletal
trials, we obtained a relatively large sample size
(n=1398 to investigate the effect of patients’ prefer-
ences on treatment outcomes and n=1583 to investi-
gatetheeffectofpatients’preferencesonattrition).The
design of this study—in which we made comparisons
between patients who received their preference,
patients who did not receive their preference, and
those with no preference—is, as far as we can
determine, novel for detecting effects of preference.
In most of the trials included in the analysis, the
questionnaires had been completed “alone” by the
participants and therefore were unlikely to have been
influenced by any treatment preference held by health
professionals or researchers involved in the trials.
Where questionnaires had been completed in the
presence of health professionals or researchers, proce-
dures had been put in place by the trialists to minimise
the influence of their treatment preferences on the
participants’ answers to the questionnaires.
Our study does have some limitations. Firstly, we
restricted our meta-analysis to musculoskeletal trials,
so our results may not be applicable to other areas of
health care. Secondly, within each of the individual
component trials participants with a very strong
preference for usual care will tend not to be recruited
into the studies. However, several studies did recruit
participants who had a preference for treatments that
were available outside of the trial setting. Thirdly, we
interpreted missing data at the first follow-up after the
intervention as attrition. We did not investigate if data
were present at the final follow-up. Fourthly, eight of
the 17 studies were identified through the personal
knowledge of one of the authors (DT), who was a co-
investigator/author on some reports and who had
found others through general reading of trial reports.
Althoughfourofthesestudieswereunpublishedatthe
time of the search, this suggests that other similar trials
exist that our search strategy did not identify. Finally,
confounding could be present—for example, actual
treatmentassociatedwithpreferencescausinganeffect.
We acknowledge that an intermediate confounding
variablemayberesponsiblefortheassociation,butwe
cannot find any evidence of a variable in such an
analysis.
Table 4 |Number (percentage) of participants included in
analysis to estimate effect of patients’ preferences on
outcomes
Preferences Frequency
Did not receive preference 331 (23.7)
Received preference 322 (23.0)
No preference/indifferent 745 (53.3)
Total 1398 (100)
Patients with missing baseline data (n=6, 0.4%) and missing follow-up
scores (n=190, 11.9%) excluded.
Table 5 |Number(percentage)ofparticipantsincludedinanalysis toestimateeffectof patients’
preferences on attrition
Preferences
Data at first follow-up
Total Data Missing data
Did not receive preference 329 (23.6) 27 (14) 356 (22.5)
Received preference 320 (23.0) 34 (18) 354 (22.4)
No preference/indifferent 744 (53.4) 129 (68) 873 (55.1)
Total 1393 (100) 190 (100) 1583 (100)
Patients with missing baseline data (n=6, 0.4%), missing data for sex (4, 0.3%), and missing data for age (1,
0.1%) excluded.
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This is the first study that we are aware of in which a
patientlevelmeta-analysishasbeendonetoinvestigate
the effects of patients’ preferences on treatment
outcomes and attrition. Our review differs from the
earlier review by King and colleagues,
5 in that we
sought only trials in which all participants had been
randomised irrespective of their preferences. Also our
study was restricted to musculoskeletal trials. The
search in the review by King and colleagues covered
theperiod1966toSeptember2004andidentifiedonly
twofullyrandomisedpatientpreferencetrials.
13w1Most
ofthetrialsidentifiedinourstudywerepublishedafter
this time, indicating that fully randomised patient
preference trials are becoming more widely used. By
using these designs, we can ensure that when we
compare patients who receive their preferred treat-
ment with those who did not receive their preferred
treatmenttheyaresimilarintermsofpotentialbaseline
confounders.
Implications
In terms of treatment effects, we did see an increased
treatment effect size among participants who were
randomised to their preferred treatment compared
with those who were indifferent to the treatment
allocation. Preferences seemed to affect outcome
despite the fact that patients with and without a
preference were balanced in the most important
variable at baseline (that is, baseline score). Whether
preferences will materially affect the overall outcome
of any one trial will depend on the proportion of
participants with a preference, the effect of the
preferenceitself,and the effectsizeofthe intervention.
Wedidnotlookattheoriginofpreferences,whichmay
involvethepersonhavinghadthatparticulartreatment
before and knowing that the treatment has helped and
what the treatment involves. In this review, we have
shown that about 57% of the participants have a
preference and those who are allocated to their
preference show about 0.162 of a standard deviation
increase in effect above those who were indifferent.
Thismighthaveanimportanteffectontheoutcomesof
a trial. If, for example, a treatment had an effect size of
0.25 among indifferent participants, then our results
suggestthatforthosewithapreferencetheeffectwould
beabout0.41(thatis,a64%increaseineffectsize).This
increased effect is not necessarily a bias—it might be a
genuine effect in the sense that the treatment works
better among patients who desire and receive their
preferredtreatment.Itcould,however,changethecost
effectiveness of a treatment. A treatment may not be
costeffectiveoverallbutcouldbeamongasubgroupof
participants who prefer that treatment.
14 However, we
cannot assume this to be true for people with strong
preferences for a treatment and who consequently did
not take part in the trials included in this study. The
behaviour of this group of people is unknown—for
example, they may become easily disappointed if the
treatment does not meet their expectations. Conse-
quently,we would concludethatin trials—particularly
when a novel therapy is available only within
the context of the study and outcomes are subjective
—pre-randomised preferences should be identified
and recorded so that they can be accounted for in any
analysis. Although an effect size of 0.162 seems to be
modest, we need to set this in the context of generally
modest effect sizes from effective treatments for
musculoskeletal problems in general. For example,
the UK BEAM trial, which evaluated manipulation
with or without exercise for the treatment of low back
pain,foundaneffectsizeof0.34forexerciseafterthree
months and an effect size of 0.39 for manipulation.
15
Our results provide no evidence that “resentful
demoralisation” leads to a reduction in effect size if
people are allocated to their undesired treatment.
Stratifyingbypreferenceswouldhelpthepowerofa
trial if either the trial was small or the proportion of
patients with a preference was small; if, for instance,
10% of participants had a preference and the trial only
had 100 participants, all 10 (or at least eight or nine)
participants with a preference might end up in one
group. Consequently, we would be unable to control
for the possible effects of preference in a regression
analysis.Therefore,insmalltrialsortrialsinwhichthe
proportion of patients with a preference is small,
trialists might consider using preference as a stratifica-
tion variable.
Conclusions
This review shows that treatment preferences affect
outcomesin a sample ofmusculoskeletal trials but that
they are not detrimental to attrition rates. The fully
randomised preference trial seems to be more widely
used now, which would enable further work to
determinethetreatmenteffectsofpatients’preferences
in different clinical conditions.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
The effect of patients’ preferences on treatment outcomes in randomised controlled trials is
uncertain
Alternative, partially randomised, trials have been designed to overcome the potential
problem of patients’ preferences in trials
An existing systematic review found no evidence that preferences influenced attrition and
some evidence of an effect on outcomes in partially randomised trials
WHAT THIS STUDY ADDS
Patients’ preferences do affect treatment outcomes in randomised controlled trials in
musculoskeletal medicine
“Resentful demoralisation” did not occur in participants who did not get their preferred
treatment
Use of the standard randomised controlled trial, which collects preference data before
randomisation,providestheopportunitytotakepreferenceeffectsintoaccountintheanalysis
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